Natera will present 20 abstracts, including two oral presentations, at the 2026 American Association for Cancer Research® (AACR) Annual Meeting, April 17-22.
We look forward to sharing these presentations alongside our academic and clinical collaborators at #AACR26. https://ow.ly/yNn050YF3LO
Dr. Lodhi shares how she can remain proactive for her potentially high risk transplant patients with routine use of the Prosperaâ„¢ test. Learn more: https://ow.ly/KRl050YCW69
#Natera #Transplant
Don't miss our upcoming webinar featuring an expert panel highlighting ultrasensitive #MRD with phased variants. #ctDNA
Register here 👉 https://ow.ly/4ntt50YCTae
A new prospective study in Clinical Cancer Research highlights how Signateraâ„¢ was able to identify older women with early-stage ER+/HER2- breast cancer who can be managed with primary endocrine therapy (pET), without surgery.
https://ow.ly/CPuK50YBV7Z
Proud to support the National Kidney Foundation at the 43rd Annual Great Chefs of the West. Our team joined an inspiring event dedicated to advancing research, expanding patient support and increasing education for those affected by kidney disease.
https://ow.ly/Ol6h50YwY0X
Minetta Liu, MD, chief medical officer for Natera oncology, recently participated in discussions about the importance of molecular residual disease testing and the role of circulating tumor DNA. Learn more about Signateraâ„¢ during an upcoming webinar: https://ow.ly/z4fA50Yvrhv
#PMWC26 #Natera #ctDNA
Join Gerald Feldman, MD, PhD and Brian Schoenfeld, MS, LCGC, in our upcoming webinar as they provide an overview of the importance of genomic testing for patients with potential rare disease and introduce you to the new Zenithâ„¢ platform from #Natera.
Register today: https://ow.ly/JOZl50YuWNB
Two new publications highlight the clinical utility of Signateraâ„¢ in anal and rectal cancers. By providing earlier insight into molecular residual disease, Signatera can support more individualized surveillance and treatment decisions. https://ow.ly/zVCZ50YuTC5
#ctDNA #Natera
Register today for our upcoming webinar with Fenting Yan, MD, PhD and Jamie McKenzie, MD highlighting three of the twelve studies presented at the San Antonio Breast Cancer Symposium (SABCS).
Reserve your spot: https://ow.ly/tLe450YtAIR
#Natera #ctDNA
Up to 1 in 5 people w/ chronic kidney disease (CKD) may have a genetic cause, & w/out genetic testing, those insights stay hidden. Identifying the underlying cause of CKD can help improve outcomes. Learn how genetic testing can support kidney health: https://ow.ly/mW9e50YsQYB
#WorldKidneyDay
Join Krzysztof Misiukiewicz, MD and Michael Krainock, MD, PhD on a live webinar as they review and discuss the latest clinical data supporting the use of Signateraâ„¢ #ctDNA molecular residual disease (MRD) testing to support HNSCC patient care.
Register here: https://ow.ly/ftph50YsAmW
Reserve your spot today for our upcoming webinar, From ASCO GU to real-world practice: Personalized tumor-informed ctDNA in bladder cancer management.
🧬Learn how leading clinicians are using #ctDNA to guide management decisions.
Register here: https://ow.ly/uTHs50Ys3hu
@vadimkoshkin.bsky.social
Don’t miss our upcoming event, Shaping the future of skin cancer: Tumor-informed ctDNA-guided intervention.
Register here: https://ow.ly/tPbL50YrR6N
#ctDNA #Natera
Here’s a snapshot from last week, when #Natera was recognized as Healthcare Technology Company of the Year!
Oded Wohl, our Vice President of Product Development and Engineering, accepted on behalf of our team and spoke about our mission. Thank you to Healthcare Technology Report for this honor.
Thank you to everyone who stopped by our booth during #CEoT2025 to speak with our team. A big thank you to symposium speakers Sanjeev Akkina, MD and Maen Abdelrahim, MD, PhD, BPharm, who presented on the intersection of oncology and transplantation.
Colorectal cancer remains one of the most common cancers worldwide. Wearing blue is one way to show support, start conversations and encourage screening. Together, we can help increase awareness and promote access to the tools that make early detection possible. 💙
#DressInBlueDay #CRCMonth #Natera
Amanda was diagnosed with stage IV CRC at 36 while pregnant. Now in survivorship, she uses Signateraâ„¢ for post-op surveillance to help manage recurrence risk. With CRC rising in people under 50, earlier detection and informed care matter more than ever. https://ow.ly/hmhE50Ypeuw
#Natera #CRCMonth
As we recognize Rare Disease Day today, we’re proud to bring this platform to clinicians and deeply grateful to everyone who contributed to making it possible. By helping shorten the diagnostic journey, we aim to expand what’s possible for patients and families seeking clarity and care.
Zenith™ was developed to address one of pediatric medicine’s most persistent challenges: achieving timely, accurate diagnoses of rare genetic conditions.
This milestone reflects the dedication of teams across the organization and our continued commitment to areas of significant unmet need.
Advances in genomics are beginning to shift that reality. Our newly launched Zenithâ„¢ rare disease test is built on a whole-genome backbone, designed to provide earlier, more comprehensive insights for complex cases.
www.natera.com/rare-disease...
For families, the search for answers can be long with patients waiting an average of four to seven years for a diagnosis, often consulting numerous specialists along the way. Nearly 80% of rare diseases have a genetic basis, yet many patients spend years without comprehensive genetic testing.
More than 7,000 rare diseases have been identified worldwide. While each condition affects a relatively small population, together they impact over 350 million people globally. The majority are genetic, often chronic and serious, and many begin in childhood.
This is an important day for Natera with the announcement of new evidence that will be shared on Signateraâ„¢ at ASCO GU. Signatera will be featured across 11 scientific abstracts, including 4 oral presentations.
https://ow.ly/2L1E50Yn1O7
American Society of Clinical Oncology #GU26 #Natera
A positive readout from the SINERGY trial, a prospective Phase 2 study in recurrent or metastatic head and neck squamous cell carcinoma, was recently presented in an oral plenary session at the 2026 Multidisciplinary Head and Neck Cancers Symposium. #MHNCS26
Read more: https://ow.ly/gsZ350Ylky9
Hello from #SMFM26! Be sure to check out our symposium, presentations and connect with our team at booth #210! See details below 👇
We recently announced the launch of EDEN, a large, multi-center prospective study designed to evaluate Natera’s NIPT for early risk assessment of preeclampsia and other serious pregnancy complications.
Read the full announcement: https://ow.ly/74IH50YccZf
We are proud to collaborate with Exelixis on the planned, phase III pivotal trial (STELLAR-316). It's another example of Natera's "Treat on Molecular Recurrence" approach, where patients will be treated with therapy if they test positive with Signateraâ„¢.
Learn more: www.natera.com/company/news...
Our expanded 21-gene Fetal Focusâ„¢ single-gene non-invasive prenatal test is now available. https://ow.ly/rfUg50XSeWM
Together with Quantum Leap Healthcare Collaborative, we’re excited to share that new findings from the I-SPY 2 trial were published in Nature Communications. This publication shows Signatera™ can predict treatment response and recurrence risk in early-stage breast cancer. https://ow.ly/BYZR50XKpKV
Findings from RenaCARE, evaluating management of CKD one year after RenasightTM testing have been published in @asnpublications.bsky.social.
Results show how genetic insights informed diagnosis, prognosis and family care decisions.
https://ow.ly/cuze50XFUAH
#CKD #Natera #Renasight
